Vasoactive peptides in cardiovascular (patho)physiology
Authors:
- Rita TostesRTRita Tostes
- Carmine SavoiaCSCarmine Savoia
- M N MuscaraMMM N Muscara
- Rhian M TouyzRTRhian M Touyz
- 1 May 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 5 (3) , 531-552
Abstract
Numerous vasoactive agents play an important physiological role in regulating vascular tone, reactivity and structure. In pathological conditions, alterations in the regulation of vasoactive peptides result in endothelial dysfunction, vascular remodeling and vascular inflammation, which are important processes underlying vascular damage in cardiovascular disease. Among the many vasoactive agents implicated in vascular (patho)biology, angiotensin II (Ang II), endothelin (ET), serotonin and natriuretic peptides appear to be particularly important because of their many pleiotropic actions and because they have been identified as potential therapeutic targets in cardiovascular disease. Ang II, ET-1, serotonin and natriuretic peptides mediate effects via specific receptors, which belong to the group of G-protein-coupled receptors. ET, serotonin and Ang II are primarily vasoconstrictors with growth-promoting actions, whereas natriuretic peptides, specifically atrial, brain and C-type natriuretic peptides, are vasodilators with natriuretic effects. Inhibition of vasoconstrictor actions with drugs that block peptide receptors, compounds that inhibit enzymes that generate vasoactive peptides or agents that increase levels of natriuretic peptides are potentially valuable therapeutic tools in the management of cardiovascular diseases. This review focuses on ET, natriuretic peptides and serotonin. The properties and distribution of these vasoactive agents and their receptors, mechanisms of action and implications in cardiovascular (patho)physiology will be discussed.Keywords
This publication has 238 references indexed in Scilit:
- Enzymatic pathways involved in the generation of endothelin‐1(1–31) from exogenous big endothelin‐1 in the rabbit aortaBritish Journal of Pharmacology, 2006
- Calcium signalling: dynamics, homeostasis and remodellingNature Reviews Molecular Cell Biology, 2003
- Tezosentan in patients with acuteheart failure and acute coronary syndromesJACC, 2003
- RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edemaJACC, 2003
- Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?International Journal of Cardiology, 2002
- A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathyEuropean Heart Journal, 2001
- Novel 31-Amino-Acid-Length Endothelins Cause Constriction of Vascular Smooth MuscleBiochemical and Biophysical Research Communications, 1998
- Dose‐ and time‐dependency of the dilator effects of the endothelin antagonist, BQ‐123, in the human forearmBritish Journal of Clinical Pharmacology, 1997
- Clearance of Circulating Endothelin-1 by ETB Receptors in RatsBiochemical and Biophysical Research Communications, 1994
- The biosynthesis of endothelin-1 by human polymorphonuclear leukocytesBiochemical and Biophysical Research Communications, 1991